Matches in SemOpenAlex for { <https://semopenalex.org/work/W4248298049> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4248298049 endingPage "1150" @default.
- W4248298049 startingPage "1142" @default.
- W4248298049 abstract "BACKGROUND To the authors' knowledge, no analysis has examined the specific components of drug spending for overall cancer care. The authors' objective was to quantify and characterize trends in outpatient drug expenditures for cancer patients. METHODS The authors retrospectively analyzed pharmacy and outpatient professional claims data from commercial and Medicare health maintenance organization enrollees with a solid tumor diagnosis in 1995 and 1998. Charges were subdivided by type of drug (antineoplastic drugs, chemotherapy adjuncts, supportive drugs, and drugs unrelated to cancer treatment). RESULTS In 1995, 14,663 cancer patients received outpatient drug treatment and 13,829 patients in 1998. Total charges increased from $17.9 million (mean charge of $1218 per patient) to $27.9 million (mean charge of $2003 per patient), an average annual increase of 16%. Antineoplastic therapy constituted the largest component of cancer-related drug costs (67%) and represented 76% of the increase from 1995 to 1998. Most charges were incurred in the professional setting for agents administered by injection. The primary explanation for the increases appeared to be a shift in treatment patterns toward newer, more expensive antineoplastic agents. Supportive therapy represented 17% of the increase in cancer drug costs, followed by chemotherapy adjuncts (7%). Charges for drugs unrelated to cancer therapy increased by 21% per year. CONCLUSIONS Antineoplastic therapy administered in an office or clinic was the single most important cost driver, with newer more expensive agents replacing older, less expensive drugs. Attempts to understand and control outpatient drug cost increases for cancer patients should focus primarily on antineoplastic therapy, especially the appropriate substitution of newer agents for older, less expensive alternatives. Some nonchemotherapy cancer drugs may offer an opportunity to improve quality of life with a relatively small effect on overall cancer drug costs. Cancer 2002;94:1142–50. © 2002 American Cancer Society. DOI 10.1002/cncr.10347" @default.
- W4248298049 created "2022-05-12" @default.
- W4248298049 creator A5008359912 @default.
- W4248298049 creator A5009875185 @default.
- W4248298049 creator A5015274357 @default.
- W4248298049 creator A5032420776 @default.
- W4248298049 creator A5032698088 @default.
- W4248298049 creator A5034329124 @default.
- W4248298049 date "2002-02-15" @default.
- W4248298049 modified "2023-09-27" @default.
- W4248298049 title "Outpatient cancer drug costs" @default.
- W4248298049 doi "https://doi.org/10.1002/cncr.10347.abs" @default.
- W4248298049 hasPublicationYear "2002" @default.
- W4248298049 type Work @default.
- W4248298049 citedByCount "0" @default.
- W4248298049 crossrefType "journal-article" @default.
- W4248298049 hasAuthorship W4248298049A5008359912 @default.
- W4248298049 hasAuthorship W4248298049A5009875185 @default.
- W4248298049 hasAuthorship W4248298049A5015274357 @default.
- W4248298049 hasAuthorship W4248298049A5032420776 @default.
- W4248298049 hasAuthorship W4248298049A5032698088 @default.
- W4248298049 hasAuthorship W4248298049A5034329124 @default.
- W4248298049 hasConcept C104863432 @default.
- W4248298049 hasConcept C121608353 @default.
- W4248298049 hasConcept C124306116 @default.
- W4248298049 hasConcept C126322002 @default.
- W4248298049 hasConcept C160735492 @default.
- W4248298049 hasConcept C162324750 @default.
- W4248298049 hasConcept C177713679 @default.
- W4248298049 hasConcept C2776694085 @default.
- W4248298049 hasConcept C2780035454 @default.
- W4248298049 hasConcept C2983331546 @default.
- W4248298049 hasConcept C3019816032 @default.
- W4248298049 hasConcept C3020110884 @default.
- W4248298049 hasConcept C500440147 @default.
- W4248298049 hasConcept C50522688 @default.
- W4248298049 hasConcept C512399662 @default.
- W4248298049 hasConcept C71924100 @default.
- W4248298049 hasConcept C98274493 @default.
- W4248298049 hasConceptScore W4248298049C104863432 @default.
- W4248298049 hasConceptScore W4248298049C121608353 @default.
- W4248298049 hasConceptScore W4248298049C124306116 @default.
- W4248298049 hasConceptScore W4248298049C126322002 @default.
- W4248298049 hasConceptScore W4248298049C160735492 @default.
- W4248298049 hasConceptScore W4248298049C162324750 @default.
- W4248298049 hasConceptScore W4248298049C177713679 @default.
- W4248298049 hasConceptScore W4248298049C2776694085 @default.
- W4248298049 hasConceptScore W4248298049C2780035454 @default.
- W4248298049 hasConceptScore W4248298049C2983331546 @default.
- W4248298049 hasConceptScore W4248298049C3019816032 @default.
- W4248298049 hasConceptScore W4248298049C3020110884 @default.
- W4248298049 hasConceptScore W4248298049C500440147 @default.
- W4248298049 hasConceptScore W4248298049C50522688 @default.
- W4248298049 hasConceptScore W4248298049C512399662 @default.
- W4248298049 hasConceptScore W4248298049C71924100 @default.
- W4248298049 hasConceptScore W4248298049C98274493 @default.
- W4248298049 hasIssue "4" @default.
- W4248298049 hasLocation W42482980491 @default.
- W4248298049 hasOpenAccess W4248298049 @default.
- W4248298049 hasPrimaryLocation W42482980491 @default.
- W4248298049 hasRelatedWork W1965636077 @default.
- W4248298049 hasRelatedWork W2029679708 @default.
- W4248298049 hasRelatedWork W2108779174 @default.
- W4248298049 hasRelatedWork W2389307321 @default.
- W4248298049 hasRelatedWork W2400818842 @default.
- W4248298049 hasRelatedWork W2410200968 @default.
- W4248298049 hasRelatedWork W2412428663 @default.
- W4248298049 hasRelatedWork W2993742447 @default.
- W4248298049 hasRelatedWork W321172187 @default.
- W4248298049 hasRelatedWork W4285386966 @default.
- W4248298049 hasVolume "94" @default.
- W4248298049 isParatext "false" @default.
- W4248298049 isRetracted "false" @default.
- W4248298049 workType "article" @default.